Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,057,778
  • Shares Outstanding, K 1,092,190
  • Annual Sales, $ 16,659 M
  • Annual Income, $ -3,990 M
  • 60-Month Beta 1.50
  • Price/Sales 0.72
  • Price/Cash Flow 2.82
  • Price/Book 1.09
Trade TEVA with:

Options Overview

Details
  • Implied Volatility 41.20%
  • Historical Volatility 35.81%
  • IV Percentile 3%
  • IV Rank 7.19%
  • IV High 146.41% on 04/30/20
  • IV Low 33.05% on 04/01/21
  • Put/Call Vol Ratio 0.46
  • Today's Volume 32,419
  • Volume Avg (30-Day) 25,231
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 880,918
  • Open Int (30-Day) 783,053

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.55
  • Number of Estimates 4
  • High Estimate 0.58
  • Low Estimate 0.54
  • Prior Year 0.73
  • Growth Rate Est. (year over year) -24.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.73 +0.28%
on 04/13/21
11.99 -10.26%
on 03/22/21
-0.03 (-0.28%)
since 03/12/21
3-Month
10.19 +5.59%
on 03/05/21
13.30 -19.10%
on 02/09/21
-0.79 (-6.84%)
since 01/13/21
52-Week
8.44 +27.49%
on 11/05/20
13.30 -19.10%
on 02/09/21
+0.43 (+4.16%)
since 04/13/20

Most Recent Stories

More News
Global Bacterial Conjunctivitis Drug Market By Product Type, By Frequency, By Application, By End User, By Region, Industry Analysis and Forecast, 2021 – 2027

New York, US, The business report released by Zion Market Research on market is focused to facilitate a deep understanding of the market definition, potential, and scope. The report is curated after deep...

AKRX : 0.0900 (-51.01%)
AGN : 193.02 (+0.02%)
BAYRY : 15.8400 (+0.19%)
MRK : 76.43 (+0.28%)
NVS : 86.61 (-0.84%)
PRGO : 40.15 (-0.91%)
PFE : 37.16 (+0.51%)
SNPHF : 13.2600 (-5.29%)
TEVA : 10.76 (-1.65%)
VRX.TO : 30.80 (-3.33%)
Teva Canada Announces New Autoinjector for AJOVY(R) for the Preventive Treatment of Migraine in Adults

--

TEVA : 10.76 (-1.65%)
Teva receives EU Marketing Authorisation for Seffalair(R) Spiromax(R) and BroPair(R) Spiromax(R) (salmeterol xinafoate / fluticasone propionate)

Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100...

TEVA : 10.76 (-1.65%)
Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 2021

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the first quarter on Wednesday, April 28, 2021 at 7:00 a.m. ET....

TEVA : 10.76 (-1.65%)
Teva Canada Amplifies Commitment to Canadian Caregivers - Introduces new resources to support and improve mental health of Caregivers

Teva Canada Amplifies Commitment to Canadian Caregivers - Introduces new resources to support and improve mental health of Caregivers

TEVA : 10.76 (-1.65%)
Teva Canada Amplifies Commitment to Canadian Caregivers

--April 6, 2021 - National Caregiver Day Event - 12:00 PM EDT

TEVA : 10.76 (-1.65%)
Hormonal Contraceptives Market to Hit USD 24,330.1 Million by 2027; Growing Focus to Cater to Unmet Contraceptive Demand Worldwide: Fortune Business Insights(TM)

The global hormonal contraceptives market size is expected to showcase considerable growth by reaching USD 24,330.1 million by 2027 while exhibiting a CAGR of 5.4% between 2020 and 2027.

MRK : 76.43 (+0.28%)
NVS : 86.61 (-0.84%)
PFE : 37.16 (+0.51%)
TEVA : 10.76 (-1.65%)
Impact of COVID-19 on Glaucoma Drugs Market Size 2021-2027 | Latest Trends, Market Share, Product Types and Application, Company Profiles, Business Overview and Performance, SWOT Analysis

The latest research report on delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrate its growth trends and...

AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 76.43 (+0.28%)
NMUS : 0.6500 (-9.52%)
NVS : 86.61 (-0.84%)
OCAT : 8.47 (+0.12%)
OCUL : 15.89 (-1.91%)
OHRP : 5.39 (+30.19%)
PRGO : 40.15 (-0.91%)
PFE : 37.16 (+0.51%)
SNPHF : 13.2600 (-5.29%)
SCMP : 18.05 (+0.28%)
TEVA : 10.76 (-1.65%)
VRX.TO : 30.80 (-3.33%)
Central Nervous System Treatment Market to Reach USD 166.53 Billion with a CAGR of 9.4% by 2028; Rising Cases of Neurological Disorders to Propel Growth: states Fortune Business Insights(TM)

The global central nervous system treatment market size is expected to reach USD 166.53 billion by 2028, exhibiting a CAGR of 9.4% during the forecast period. The surge in chronic neurological illness...

NVS : 86.61 (-0.84%)
PFE : 37.16 (+0.51%)
TEVA : 10.76 (-1.65%)
Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study

Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

TEVA : 10.76 (-1.65%)
AZN : 49.19 (-0.47%)
GSK : 36.04 (-0.06%)
AMGN : 249.95 (+0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

3rd Resistance Point 11.10
2nd Resistance Point 11.02
1st Resistance Point 10.89
Last Price 10.76
1st Support Level 10.68
2nd Support Level 10.60
3rd Support Level 10.47

See More

52-Week High 13.30
Fibonacci 61.8% 11.44
Fibonacci 50% 10.87
Last Price 10.76
Fibonacci 38.2% 10.30
52-Week Low 8.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar